Analysts expect Dermata Therapeutics, Inc. to report revenue of 0.00 for 2021, against a range of 0.00 to 0.00. The most recent reported year, 2025, came in at 0.00.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | - | 0.00 | ||||
| High Estimate | 0.00 | 0.00 | 0.00 | ||||
| Low Estimate | 0.00 | 0.00 | 0.00 | ||||
| Consensus Estimate | 0.00 | 0.00 | 0.00 |
Analysts expect Dermata Therapeutics, Inc. to report earnings per share of -0.58 for Q3 26, against a range of -0.64 to -0.52. The most recent reported quarter, Q2 26, came in at -0.74, a 39.6% miss against the -0.53 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -20.40 | -13.40 | -4.50 | -1.66 | -1.65 | -0.35 | -0.48 | -0.74 | - | - | - | - | - | - | - | - | ||
| High Estimate | -24.55 | -14.47 | -4.44 | -2.83 | -1.56 | -1.40 | -0.50 | -0.50 | -0.52 | -0.42 | -0.41 | -0.32 | 1.79 | 3.32 | 3.25 | 1.89 | ||
| Low Estimate | -26.19 | -16.23 | -5.02 | -3.19 | -1.72 | -1.60 | -0.54 | -0.56 | -0.64 | -0.46 | -0.47 | -0.38 | 1.51 | 3.00 | 3.05 | 1.73 | ||
| Consensus Estimate | -25.37 | -15.35 | -4.73 | -3.01 | -1.64 | -1.50 | -0.52 | -0.53 | -0.58 | -0.44 | -0.44 | -0.35 | 1.65 | 3.16 | 3.15 | 1.81 |